AI Article Synopsis
- Prostate cancer is a common cancer among men, and this study investigates whether glucagon-like peptide 1 receptor agonists (GLP-1 RAs), usually used for treating type 2 diabetes, can reduce the risk of developing this cancer.
- The research included a systematic review of five studies from various countries, which found that GLP-1 RA use is associated with a significant 28% reduction in prostate cancer risk compared to other treatments.
- The study concludes that GLP-1 RAs could play a role in reducing prostate cancer risk, especially for men with diabetes, but further research is needed to understand how these drugs work in this context and to examine different patient variables.
Article Abstract
Background: Prostate cancer is one of the most prevalent malignancies among men globally. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), primarily used for type 2 diabetes mellitus (T2DM) management, have been investigated for their potential effects on cancer risks. This systematic review and meta-analysis aimed to assess the association between GLP-1 RA use and risk reduction of prostate cancer.
Methods: A comprehensive literature search was conducted across PubMed, Embase, and Web of Science up to July 30, 2024. Studies that met the inclusion criteria randomized controlled trials, cohort studies, case-control studies, and observational studies assessing the incidence of prostate cancer in GLP-1 RA-treated patients were included. The quality of studies was evaluated using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias tool. Meta-analysis was performed using a random effects model.
Results: A total of five studies were included, analyzing data from diverse international contexts. The included studies showed a reduced risk of prostate cancer with both adjusted and unadjusted effect estimates with GLP-1 RAs. The meta-analysis revealed an RR of 0.72 (95% CI: 0.610 to 0.832), indicating a statistically significant 28% reduction in prostate cancer risk associated with GLP-1 RA use compared to placebo or other antidiabetic drugs. Moderate heterogeneity was observed (I = 51%). Sensitivity analysis confirmed the results.
Conclusion: The findings suggest a significant protective association between GLP-1 RA use and reduced prostate cancer risk in men, particularly those with T2DM. This supports the potential of GLP-1 RAs not only in diabetes management but also as a strategy to mitigate cancer risk. Further research is required to confirm these findings and explore the underlying mechanisms, considering different dosages, durations of therapy, and patient subgroups based on demographic and metabolic characteristics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-024-04266-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!